Vancomycin in Primary Sclerosing Cholangitis in Italy

Launched by UNIVERSITY OF MILANO BICOCCA · May 16, 2023

Keywords

ClinConnect Summary

This clinical trial, titled "Vancomycin in Primary Sclerosing Cholangitis in Italy," is investigating the safety and effectiveness of an antibiotic called vancomycin for treating a liver disease known as primary sclerosing cholangitis (PSC). PSC is a long-lasting condition that damages the bile ducts and can lead to serious liver problems. In this study, participants aged between 15 and 70 will receive either a low or high dose of vancomycin or a placebo (a sugar pill with no active ingredients) for a set period. Researchers hope to find out if vancomycin can help slow down the progression of PSC or improve symptoms.

To be eligible for the trial, participants must be diagnosed with PSC based on specific medical imaging tests, have certain levels of liver enzymes, and be free from other serious liver conditions. Candidates should also not have taken certain medications or antibiotics recently and must agree to follow specific guidelines regarding contraception if they are of childbearing age. Those who join the trial can expect regular check-ups and tests to monitor their health throughout the study. It's important to note that this trial is still recruiting participants, so there may be opportunities for eligible individuals to contribute to this important research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Willing and able to give informed consent prior to any study specific procedure being performed;
• • 2. Male and non-pregnant, non-lactating female subjects, including women of child bearing potential (WOCBP), between 15-70 years of age at the time of informed consent;
• • 3. Diagnosis of large-duct PSC based on cholangiogram (at MRCP, ERCP, PTC) according to the most recent published guidelines (EASL);
• • 4. Baseline ALP ≥1.5 times upper limit normal at screening;
• • 5. Absence of biliary obstruction and/or malignancy within 6-12 months of entry into the study;
• • 6. If a patient is on ursodeoxycholic acid (UDCA) or 5-aminosalicylic acid he or she is expected to remain on the same daily dose during the study period;
• • 7. Patients who received antibiotics or probiotics may participate if they had a washout period of at least 3-month prior to study entry;
• • 8. If a patient has been on obeticholic acid or other experimental therapies (e.g. cilofexor and norUDCA) for PSC, they must complete a 3-month washout period before study entry;
• • 9. PSC with or without IBD. IBD diagnosis should be documented and with a minimum disease duration of 6 months, as determined by endoscopic and histopathology assessment. IBD should be in clinical remission or mildly active according to CDAI and partial Mayo score for CD and UC, respectively (i.e. patients with CDAI score \< 220 and pMayo score \<5). Patients without documented IBD need a colonoscopy with segmental biopsies within 12 months prior to baseline visit;
• • 10. Female subjects of childbearing potential must test negative for pregnancy at screening, baseline and follow-up visits and if engage in sexual intercourse must agree to use specific methods of contraception.
• • 11. Male subjects with female partners of childbearing potential must use condoms during treatment and until the end of relevant systemic exposure.
• Exclusion Criteria:
• • 1. Receiving an antibiotic or probiotic within 3 months prior to the study;
• • 2. Expected to receive antibiotics within the weeks leading up to enrollment (such as patients with recurrent cholangitis, ongoing infectious illnesses, etc.);
• • 3. Allergy to vancomycin or teicoplanin;
• • 4. Biliary intervention within 3 months prior to study enrollment or planned;
• • 5. Alcohol abuse (defined as greater than 14 standard drinks units per week in men; greater than 7 standard drinks units per week);
• • 6. Pregnancy and lactation;
• • 7. Advanced renal disease (GFR\< 70);
• • 8. Active hepatitis B and/or C infection;
• • 9. Other chronic or cholestatic liver diseases such as PBC, autoimmune hepatitis, nonalcoholic steatohepatitis, alcoholic liver disease, Wilson's disease, hemochromatosis, α-1 antitrypsin deficiency, IgG4-related sclerosing cholangitis, and liver cancer;
• • 10. History of CCA;
• • 11. Advanced liver disease (history of variceal bleeding, ascites, hepatic encephalopathy, and/or bilirubine \>4 mg/dL);
• • 12. On active transplantation list;
• • 13. IBD with uncontrolled moderate to severe activity;
• • 14. Active treatment or within the previous four weeks (washout period) with any immunosuppressive medication for controlling IBD (i.e. azathioprine, 6-mercaptopurine, tacrolimus, methotrexate, infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, ozanimod). Treatment with corticosteroids (including budesonide, budesonide MMX and beclomethasone) in the previous four weeks
• • 15. Active treatment with rifampicin or within the previous three months (washout period);
• • 16. Dose change within last 3 months prior to baseline of concomitant treatment with vitamin D or fibrates;
• • 17. Treatment with any experimental drug within the previous three months;
• • 18. Any known relevant infectious disease (e.g. active tuberculosis, AIDS defining disease);
• • 19. History or active hearing problems;
• • 20. Any active malignant disease;
• • 21. Well found doubt about patient's cooperation, e.g. addiction to alcohol or drugs;
• • 22. Imprisoned person, person admitted to nursing homes, persons under legal guardianship, and persons not able to express their consent.